Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib.

Molecular cancer therapeutics - 1 Dec 2012

Acquaviva Jaime, Smith Donald L, Sang Jim, Friedland Julie C, He Suqin, Sequeira Manuel, Zhang Chaohua, Wada Yumiko, Proia David A

Abstract excerpt

Mutant KRAS is a feature of more than 25% of non-small cell lung cancers (NSCLC) and represents one of the most prevalent oncogenic drivers in this disease. NSCLC tumors with oncogenic KRAS respond poorly to current therapies, necessitating the pursuit of new treatment strategies. Targeted inhibition of the molecular chaperone Hsp90 results in the coordinated blockade of multiple oncogenic signaling pathways in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzimidazoles
Share to Imidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mice, Nude

Share to Phosphoinositide-3 Kinase Inhibitors

Share to Quinolines

Share to TOR Serine-Threonine Kinases

Share to Triazoles

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 23012248
DOI: 10.1158/1535-7163.MCT-12-0615

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib.PMID 23012248Read ↗

The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.Semantic proximity Read ↗

Acquired Resistance to the Hsp90 Inhibitor, Ganetespib, in KRAS-Mutant NSCLC Is Mediated via Reactivation of the ERK-p90RSK-mTOR Signaling Network.Semantic proximity Read ↗

Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non–Small Cell Lung CancerSemantic proximity Read ↗

A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer.Semantic proximity Read ↗

Dual Inhibitors of KRASG12D and HSP90 Are Effective against KRASG12D Inhibitor Resistance.Semantic proximity Read ↗

The HSP90 inhibitor, NVP-AUY922, attenuates intrinsic PI3K inhibitor resistance in KRAS-mutant non-small cell lung cancer.Semantic proximity Read ↗

The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.Semantic proximity Read ↗

HSP90 inhibitors in lung cancer: promise still unfulfilled.Semantic proximity Read ↗

Chaperone directed heterobifunctional molecules circumvent KRASG12C inhibitor resistance.Semantic proximity Read ↗

Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells.Semantic proximity Read ↗

WEE1 confers resistance to KRASG12C inhibitors in non-small cell lung cancer.Semantic proximity Read ↗

Reactivation of the p90RSK-CDC25C Pathway Leads to Bypass of the Ganetespib-Induced G2-M Arrest and Mediates Acquired Resistance to Ganetespib in KRAS-Mutant NSCLC.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.